Overall sensitivity of 88% for PD participants and specificity of 96.3% for healthy controls. Positive CSF α-syn SAA in 86% of at-risk individuals (RBD or hyposmia). Sensitivity lower in LRRK2 mutation carriers, higher (99%) in patients with olfactory deficit. The gene discussed is LRRK2; the disease is Parkinson disease.